PTPRC and neoplasm: Inducing tumor suppression and lymphocytotoxicity Decreasing Tregs and increasing the infiltration of CD45+ immune cells and CD4+ or CD8+ T cells Inducing the release of IFN‐γ, perforin, and granzyme Extending the OS rate compared with monotherapy with M1